Key Highlights: Implications: Zydus’ smart-pen assault smashes generic pricing barriers, handing endocrinologists flexible dosing that trumps competitor pens while exploding Tier-2 a...
Key Highlights: Implications: Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic...
Key Highlights: Implications: PEPAIR smashes cost barriers to OPEP therapy, handing pulmonologists a game-changing tool that slots perfectly alongside Zydus inhalers and Deriphyllin....
